Skip to main content Accessibility help
×
Home

INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES

  • Sonja V. Sorensen (a1), Jo Wern Goh (a2), Feng Pan (a2), Connie Chen (a3), Denise Yardley (a4), Miguel Martín (a5), Kevin Knopf (a2), Ágnes Benedict (a2), Carla Giorgetti (a6) and Shrividya Iyer (a6)...

Abstract

Objectives: This study aims to estimate the annual U.S. societal costs associated with treatment of metastatic breast cancer (MBC) patients using an incidence-based cost-of-illness (COI) framework.

Methods: An incidence-based COI model was constructed in which MBC patients were simulated from diagnosis through active treatment, palliative care, and death over 5 years. Key model parameters included: annual incidence of breast cancer in the metastatic stage, utilization of cancer therapies and other medical care resources, treatment-related adverse events, unit costs, work days missed by patient and caregiver, and wage rates. Overall survival was based on SEER data and costs were assigned to living patients monthly, according to their disease management phase. The outcomes measures were total discounted societal costs, cost/year, and cost/patient-year.

Results: The annual incidence of MBC in the United States in 2007 was estimated to be 49,674 patients (de novo and progressed from earlier stages). The total discounted cost to society attributable to MBC was $12.2 billion for the incident cohort, or $98,571 per patient-year. The 5-year direct medical cost of this incident cohort was $9.3 billion, or $75,415 per patient-year. Treatment-related costs (active treatment, toxicity management, and medical follow-up) contributed 44 percent of MBC expenditure, followed by palliative/best supportive care costs (31 percent). Lost productivity accounted for approximately 21 percent of the total cost ($2.6 billion over 5 years or $21,153 per patient-year).

Conclusions: The societal burden of MBC in the United States is substantial. Earlier detection and effective treatment could lead to a significant decrease in costs while improving overall disease prognosis.

Copyright

References

Hide All
1.Allen, JM. Economic/societal burden of metastatic breast cancer: A US perspective. Am J Manag Care. 2010;16:697704.
2.Barron, JJ, Quimbo, R, Nikam, PT, Amonkar, MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109:367377.
3.Bennett, CL, Calhoun, EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients. Oncologist. 2007;12:478483.
4.Berkowitz, N, Gupta, S, Silberman, G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3:2330.
5.Brewster, AM, Hortobagyi, GN, Broglio, KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100:11791183.
6.Bureau of Labor Statistics. News release: The employment situation - April 2011. Washington, DC: U.S. Department of Labor; 2011.
7.Bureau of Labor Statistics. Table 22: Persons at work in nonagricultural industries by age, sex, race, Hispanic or Latino ethnicity, marital status, and usual full- or part-time status. U.S. Department of Labor; 2010.
8.Bureau of Labor Statistics & U.S. Census Bureau. Current Population Survey, Design and Methodology. Technical Paper TP63RV. Washington, DC: U.S. Department of Labor and U.S. Department of Commerce, Economics and Statistics Administration; 2010.
9.Campbell, JD, Ramsey, SD.The costs of treating breast cancer in the US: A synthesis of published evidence. Pharmacoeconomics. 2009;27:199209.
10.Davis, KL, Iyer, S, Candrilli S. Predictors of the direct costs of breast cancer in the United States elderly population. Value Health. 2010;13:A260.
11.Elting, LS, Shih, YC. The economic burden of supportive care of cancer patients. Support Care Cancer. 2004;12:219226.
12.Hartmann, LC, Zahasky, KM, Grendahl, DC. Management of cancer pain. Safe, adequate analgesia to improve quality of life. Postgrad Med. 2000;107:267272, 75-76.
13.Hayman, JA, Langa, KM, Kabeto, MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. 2001;19:32193225.
14.Kruse, GB, Amonkar, MM, Smith, G, et al. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008;14:844857.
15.Kurian, AW, Thompson, RN, Gaw, AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25:634641.
16.Lamerato, L, Havstad, S, Gandhi, S, et al. Economic burden associated with breast cancer recurrence: Findings from a retrospective analysis of health system data. Cancer. 2006;106:18751882.
17.Mauri, D, Polyzos, NP, Salanti, G, et al. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100:17801791.
18.Montazeri, A. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32.
19.National Cancer Institute. Cancer trends progress report – 2009/2010 uapdate. Bethesda, MD: NIH, DHHS; April 2010.
20.National Cancer Institute. Surveillance Epidemiology and End Results (SEER) - Breast cancer. 2007–2010. Bethesda, MD: National Cancer Institute.
21.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2011. Fort Washington, PA: National Comprehensive Cancer Network.
22.Printz, C. Healthcare reform affects cancer on many fronts. More coverage for treatment and prevention planned. Cancer. 2010;116:35253526.
23.Rao, S, Kubisiak, J, Gilden, D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83:2532.
24.Schwartz, J. Current combination chemotherapy regimens for metastatic breast cancer. Am J Health Syst Pharm. 2009;66 (Suppl 6):S3S8.
25.Sloss, EM, Wickstrom, SL, McCaffrey, DF, et al. Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditions. Cerebrovasc Dis. 2004;18:815.
26.Stokes, ME, Thompson, D, Montoya, EL, et al. Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-medicare data. Value Health. 2008;11:213220.
27.Wang, SJ, Fuller, CD, Choi, M, Thomas, CR. A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer. Gastrointest Cancer Res. 2008;2:5763.
28.Yabroff, KR, Lawrence, WF, Clauser, S, et al. Burden of illness in cancer survivors: Findings from a population-based national sample. J Natl Cancer Inst. 2004;96:13221330.

Keywords

Type Description Title
WORD
Supplementary materials

Sorensen et al. supplementaey material
SUpplementary data

 Word (49 KB)
49 KB

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed